Mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats

Phytotherapy Research

Volumn 24, Issue 6, 2010, Pages 893-899

  Li, Xuan ^a   Cui, Xiaobing ^a   Sun, Xiaoyu ^a   Li, Xiaodong ^a   Zhu, Quan ^a   Li, Wei ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Diabetic nephropathy; Extra cellular matrix; Mangiferin; Transforming growth factor beta 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; COLLAGEN TYPE 4; CREATININE; GLUCOSE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MANGIFERIN; SORBITOL; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE COURSE; ERYTHROCYTE; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GLOMERULUS; GLUCOSE BLOOD LEVEL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; MESANGIUM CELL; NONHUMAN; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; URINARY EXCRETION;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE IV; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GLUTATHIONE PEROXIDASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPOGLYCEMIC AGENTS; MALE; MALONDIALDEHYDE; MANGIFERA; MESANGIAL CELLS; RATS; RATS, WISTAR; SORBITOL; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; XANTHONES;

ANEMARRHENA ASPHODELOIDES; MANGIFERA INDICA; RATTUS;

EID: 77953263473     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3045     Document Type: Article

References (27)

1. Bilous RW, Mauer SM, Sutherland DE, Steffes MW. 1989. Mean glomerular volume and rate of development of diabetic nephropathy. Diabetes 38: 1142-1147.
2. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
3. Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, Fang X, Yu B, Breyer MD, Guan Y. 2007. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 56: 2036-2045.
4. Cove-Smith A, Hendry BM. 2008. The regulation of mesangial cell proliferation. Nephron Exp Nephrol 108: e74-e79.
5. Dunlop M. 2000. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 77: S2-S12.
6. Guhua Z, Cai L, Lu C. 2004. Advanced glycation end products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol 165: 2033-2043. (Pubitemid 39578381)
7. Gupta S, Chough E, Daley J, Oates P, Tornheim K, Ruderman NB, Keaney JF Jr. 2002. Hyperglycemia increases endothelial superoxide that impairs smooth muscle cell Na+- K+-ATPase activity. Am J Physiol Cell Physiol 282: C560-C566.
8. Haneda M, Koya D, Isono M, Kikkawa R. Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14: 1374-1382.
9. Huang TH, Peng G, Li GQ, Yamahara J, Roufogalis BD, Li Y. 2006. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha. Toxicol Appl Pharmacol 210: 225-235.
10. Ichiki H, Miura T, Kubo M, Ishihara E, Komatsu Y, Tanigawa K, Okada M. 1998. New antidiabetic compounds, mangiferin and its glucoside. Biol Pharm Bull 21: 1389-1390. (Pubitemid 29021810)
11. Jafar TH, Schmid CH, Levey AS. 2005. Serum creatinine as maker of kidney function in south Asians: a study of reduced GFR in adults in Pakistan. J Am Soc Nephrol 16: 1413-1419.
12. Josephine MF, Melinda TC, Mark EC. 2008. Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes. Diabetes 57: 1446-1454.
13. Makino H, Miyamoto Y, Sawai K, Mori K, Mukoyama M, Nakao K, Yoshimasa Y, Suga S. 2006. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 55: 2747-2756.
14. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. 1984. Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155.
15. Miura T, Ichiki H, Hashimoto I, Iwamoto N, Kato M, Kubo M, Ishihara E, Komatsu Y, Okada M, Ishida T, Tanigawa K. 2001. Antidiabetic activity of a xanthone compound, mangiferin. Phytomedicine 8: 85-87. (Pubitemid 32267089)
16. Mogensen CE, Christensen CK, Vittinghus E. 1983. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 Suppl 2: 64-78.
17. Münch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, Niwa T, Lemeke HD, Schinzel R. 1997. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35: 669-677. (Pubitemid 27453364)
18. Muruganandan S, Gupta S, Kataria M, Lal J, Gupta PK. 2002. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology 176: 165-173.
19. Muruganandan S, Srinivasan K, Gupta S, Gupta PK, Lal J. 2005. Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats. J Ethnopharmacol 97: 497-501.
20. Rahn KH, Heidenreich S, Brückner D. 1999. How to assess glomerular function and damage in humans. J Hypertens 17: 309-317.
21. Park I, Kiyomoto H, Abboud SL, Abboud HE. 1997. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 46: 473-480. (Pubitemid 27090278)
22. Prabhu S, Jainu M, Sabitha KE, Shyamala Devi CS. 2006. Effect of mangiferin on mitochondrial energy production in experimentally induced myocardial infarcted rats. Vascul Pharmacol 44: 519-525.
23. Robert L, Menasche M, Robert AM, Renard G. 2006. Effect of high glucose concentration on corneal collagen biosynthesis. Ophthalmologica 220: 317-322.
24. Rossing P. 2006. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 6: 479-483.
25. Tang SY, Whiteman M, Peng ZF, Jenner A, Yong EL, Halliwell B. 2004. Characterization of antioxidant and antiglycation properties and isolation of active ingredients from traditional chinese medicines. Free Radic Biol Med 36: 1575-1587.
26. Vlassara H, Brownlee M, Cerami A. 1985. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci U S A 82: 5588-5592.
27. Yoshikawa M, Nishida N, Shimoda H, Takada M, Kawahara Y, Matsuda H. 2001. Polyphenol constituents from Salacia species: quantitative analysis of mangiferin with alphaglucosidase and aldose reductase inhibitory activities. Yakugaku Zasshi 121: 371-378.